Pathological characteristics, PCNA labeling index and DNA index in prognostic evaluation of patients with moderately differentiated hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 8, Issue 6, 2002, Pages 1040-1044

  Zeng, Wen Jiao ^a   Liu, Guo Yuan ^a   Xu, Jie ^a   Zhou, Xin Da ^a   Zhang, Yue E ^a   Zhang, Nong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER CELL; CANCER TISSUE; CELL DIFFERENTIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; FEULGEN STAINING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LIVER CELL CARCINOMA; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROGNOSIS; TUMOR EMBOLISM; TUMOR NECROSIS;

EID: 0036899152     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v8.i6.1040     Document Type: Article

References (30)

1. Tang ZY. Hepatocellular carcinoma-cause, treatment and metastasis. World J Gastroenterol 2001; 7: 445-454
2. Niu Q, Tang ZY, Ma ZC, Qin LX, Zhang LH. Serum vascular endothelial growth factor is a potential biomarker of metastatic recurrence after curative resection of hepatocellular carcinoma. World J Gastroenterol 2000; 6: 565-568
3. Giannelli G, Pierri F, Trerotoli P, Marinosci F, Serio G, Schiraldi O, Antonaci S. Occurrence of portal vein tumor thrombus in hepatocellular carcinoma affects prognosis and survival. A retrospective clinical study of 150 cases. Hepatol Res 2002; 24: 50-59
4. Dohmen K, Shirahama M, Onohara S, Miyamoto Y, Torri Y, Irie K, Ishibashi H. Differences in survival based on the type of follow-up for the detection of hepatocellular carcinoma: An analysis of 547 patients. Hepatol Res 2000; 18: 110-121
5. Fan J, Wu ZQ, Tang ZY, Zhou J, Qiu SJ, Ma ZC, Zhou XD, Ye SL. Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein. World J Gastroenterol 2001; 7: 28-32
6. Zhao WH, Ma ZM, Zhou XR, Feng YZ, Fang BS. Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score. World J Gastroenterol 2002; 8: 237-242
7. Yoong KF, Mcnab G, Hübscher SG, Adams DH. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltration lymphocytes to tumor endothelium in human hepatocellular carcinoma. J Immunol 1998; 160:3978-3988
8. Yoong KF, Afford SC, Jones R, Aujla P, Qin S, Price K, Hubscher SG, Adams DH. Expression and function of CXC and CC chemokines in human malignant liver tumors: A role for human monokine induced by γ-interferon in lymphocyte recruitment to hepatocellular carcinoma. Hepatology 1999; 30: 100-111
9. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet 2000; 356: 802-807
10. Lara-Pezzi E, Majano PL, Yáñez-Mó M, Gómez-Gonzalo M, Carretero M, Moreno-Otero R, Sánchez-Madrid F, López-Cabrera M. Effect of the hepatitis B virus HBx protein on integrin-mediated adhesion to and migration on extracellular matrix. J Hepatol 2001; 34: 409-415
11. Westermarck J, Kähäri V-M. Regulation of matrix metalloproteinase expression in tumor invasion. The FASEB J 1999; 13: 781-792
12. McKenna GJ, Chen Y, Smith RM, Meneghetti A, Ong C, McMaster R, Scudamore CH, Chung SW. A role for matrix metalloproteinases and tumor host interaction in hepatocellular carcinomas. Am J Surg 2002; 183: 588-594
13. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochim Biophys Acta 2000; 1477: 267-283
14. Lichtinghagen R, Musholt PB, Lein M, Römer A, Rudolph B, Kristiansen G, Hauptmann S, Schnorr D, Loening SA, Jung K. Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. Eur Urol 2002; 42: 398-406
15. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, Reich R. The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol 2002; 187: 39-45
16. Ohmiya N, Matsumoto S, Yamamoto H, Baranovskaya S, Malkhosyan SR, Perucho M. Germline and somatic mutations in hMSH6 and hMSH3 in gastrointestinal cancers of the microsatellite mutator phenotype. Gene 2001; 272: 301-313
17. Martin G, Halwani F, Shibata H, Meterissian S. Value of DNA ploidy and S-phase fraction as prognostic factors in stage III cutaneous melanoma. Can J Surg 2000; 43: 29-33
18. Gschwendtner A, Fend F, Hoffmann Y, Krugmann J, Klingler PJ, Mairinger T. DNA-ploidy analysis correlates with the histogenetic classification of thymic epithelial tumours. J Pathol 1999; 189: 576-580
19. Matturri L, Biondo B, Cazzullo A, Colombo B, Giordano F, Guarino M, Pallotti F, Turconi P, Lavezzi AM. Prognostic significance of different biological markers (DNA index, PCNA index, apoptosis, p53, Karyotype) in 126 adenocarcinoma gastric biopsies. Anticancer Res 1998; 18: 2819-2826
20. Mastronardi L, Guiducci A, Buttaro FM, Cristallinin EG, Puzzilli F, Maira G. Relationships among DNA Index, S-Phase, and invasive behavior in anterior pituitary adenomas. A cytometric study of 61 cases with Feulgen-positive DNA analysis. Surg Neurol 2001; 56: 27-32
21. Imai Y, Sasaki T, Fujibayashi T. Volume-corrected mitotic index as a prognostic factor in oral squamous cell carcinomas. Oral Oncol 2001; 37: 72-76
22. Krušlin B, Višnjie A, Cizmie A, Tomicic I, Kos M, Jukie S, Seiwerth S, DNA ploidy analysis and cell proliferation in congenital sacrococcygeal teratomas. Cancer 2000; 89: 932-937
23. Celis JE, Madsen P, Celis A, Nielsen HV, Gesser B. Cyclin (PCNA, auxiliary protein of DNA polymerase δ) is a central component of the pathway(s) leading to DNA replication and cell division. FEBS Lett 1987; 220: 1-7
24. Donato MF, Arosio E, Ninno ED, Ronchi G, Lampertico P, Morabito A, Balestrieri MR, Colombo M. High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity. Hepatology 2001; 34: 523-528
25. Wu P-C, Lau VK-T, Fang JW-S, Lai VC-H, Lai C-L, Lau JY-N. Imbalance between cell proliferation and cellular DNA fragmentation in hepatocellular carcinoma. Liver 1999; 19: 444-451
26. Closset J, Van De Stadt J, Delhaye M, EI Nakadi I, Lambilliotte JP, Gelin M. Hepatocellular carcinoma: Surgical treatment and prognostic variables in 56 patients. Hepatogastroenterology 1999; 46: 2914-2918
27. Tamano M, Sugaya H, Oguma M, Iijima M, Yoneda M, Murohisa T, Kojima K, Kuniyoshi T, Majima Y, Hashimoto T, Terano A. Serum and tissue PIVKA-II expression reflect the biological malignant potential of small hepatocellular carcinoma. Hepatol Res 2002; 22: 261-269
28. Aoyagi Y, Mita Y, Suda T, Kawai K, Kuroiwa T, Igarashi M, Kobayashi M, Waguri N, Asakura H. The fucosylation index of serum α-fetoprotein as useful prognostic factor in patients with hepatocellular carcinoma in special reference to chronological changes. Hepatol Res 2002; 23: 287-295
29. Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY, Tang HB. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J Cancer Res Clin Oncol 2000; 126: 641-646
30. Shimad M, Rikimaru T, Hamatsu T, Yamashita Y, Terashi T, Taguchi K, Tanaka S, Shirabe K, Sugimachi K. The role of macroscopic classification in nodular-type hepatocellular carcinoma. Am J Surg 2001; 182: 177-182